Dr. Sudhir Kumar of Indraprastha Apollo Hospital said this citing a recent study published in Neurology Clinical Practice Journal.
Led by researchers at the University of Maryland in the US, the study shows that acid-reducing medications, including proton pump inhibitors (PPIs) such as omeprazole and esomeprazole, histamine H2-receptor antagonists (H2RAs), H blockers such as Cimetidine and. Famotidine. , and antacid supplements, are associated with a higher risk of migraine and other severe headaches compared with people who do not take these medications.
"People who suffer from migraines or other severe headaches, and are taking a PPI or H2RA to treat gastrointestinal symptoms, may want to consider taking these medications to see if their headaches are alleviated," "It may make sense to stop," the doctor wrote in a post. ,
The study found that PPI use was associated with a 70 percent higher risk of migraine and other headaches, while H2RA use was associated with a 40 percent higher risk.
"It is possible that these observed associations are related to co-morbidity between gastrointestinal (GI) conditions and migraine disease and symptoms," said D. Sudhir.
He said several studies have observed an association between migraine and the presence of GI conditions including Helicobacter pylori infection, irritable bowel syndrome, celiac disease, peptic ulcers, gastroparesis and GERD.
“New cases of migraine have been reported after starting PPI/H2RA therapy, so further studies are needed to establish a cause-effect relationship,” Dr. Sudhir said.
Led by researchers at the University of Maryland in the US, the study shows that acid-reducing medications, including proton pump inhibitors (PPIs) such as omeprazole and esomeprazole, histamine H2-receptor antagonists (H2RAs), H blockers such as Cimetidine and. Famotidine. , and antacid supplements, are associated with a higher risk of migraine and other severe headaches compared with people who do not take these medications.
"People who suffer from migraines or other severe headaches, and are taking a PPI or H2RA to treat gastrointestinal symptoms, may want to consider taking these medications to see if their headaches are alleviated," "It may make sense to stop," the doctor wrote in a post. ,
The study found that PPI use was associated with a 70 percent higher risk of migraine and other headaches, while H2RA use was associated with a 40 percent higher risk.
"It is possible that these observed associations are related to co-morbidity between gastrointestinal (GI) conditions and migraine disease and symptoms," said D. Sudhir.
He said several studies have observed an association between migraine and the presence of GI conditions including Helicobacter pylori infection, irritable bowel syndrome, celiac disease, peptic ulcers, gastroparesis and GERD.
“New cases of migraine have been reported after starting PPI/H2RA therapy, so further studies are needed to establish a cause-effect relationship,” Dr. Sudhir said.
